Study		Exclusion reasons	Remarks	Reference(s)
PRISM, 2019	randomized controlled trial	inadequate or absent control group	phase II trial to evaluate whether administering IPI once every 12 weeks (modified), instead of once every 3 weeks (standard), in combination with NIVO, is associated with a favorable toxicity profile.	Buckley BMC Cancer 2019; 19:1102 10.1186/s12885-019-6273-1 Naveen S. Vasudev JCO 42, 312-323(2024) 10.1200/JCO.23.00236